Abbott Laboratories banner

Abbott Laboratories
F:ABL

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
F:ABL
Watchlist
Price: 83.02 EUR 1.54% Market Closed
Market Cap: €144.4B

EV/EBIT

19.2
Current
34%
Cheaper
vs 3-y average of 28.9

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
19.2
=
Enterprise Value
€166.8B
/
EBIT
$8.5B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
19.2
=
Enterprise Value
€166.8B
/
EBIT
$8.5B

Valuation Scenarios

Abbott Laboratories is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (28.9), the stock would be worth €125.08 (51% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+51%
Average Upside
25%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 19.2 €83.02
0%
3-Year Average 28.9 €125.08
+51%
5-Year Average 28.1 €121.62
+46%
Industry Average 19.2 €83.39
+0%
Country Average 19.6 €85
+2%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
€166.8B
/
Apr 2026
$8.5B
=
19.2
Current
€166.8B
/
Dec 2026
$11.5B
=
14.5
Forward
€166.8B
/
Dec 2027
$12.5B
=
13.3
Forward
€166.8B
/
Dec 2028
$13.6B
=
12.2
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
US
Abbott Laboratories
F:ABL
161B EUR 19.2 25.7
US
Intuitive Surgical Inc
NASDAQ:ISRG
160.3B USD 52.2 56.1
US
Stryker Corp
NYSE:SYK
129.4B USD 23.9 38.6
IE
Medtronic PLC
NYSE:MDT
105.2B USD 18.5 22.8
US
Boston Scientific Corp
NYSE:BSX
88.3B USD 24.4 30.5
DE
Siemens Healthineers AG
XETRA:SHL
42.9B EUR 16 20.3
US
Edwards Lifesciences Corp
NYSE:EW
46.3B USD 25.7 43.1
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.4B USD 33.5 42.8
US
Becton Dickinson and Co
NYSE:BDX
44.6B USD 17 25.4
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
32.9B USD 13.8 15.8
US
Resmed Inc
NYSE:RMD
32.9B USD 16.9 21.7

Market Distribution

In line with most companies in the United States of America
Percentile
43nd
Based on 8 638 companies
43nd percentile
17.5
Low
0 — 13.6
Typical Range
13.6 — 27.8
High
27.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.6
Median 19.6
70th Percentile 27.8
Max 1 826 183.2

Abbott Laboratories
Glance View

Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.

ABL Intrinsic Value
LOCKED
Unlock
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett